Status:
UNKNOWN
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak
Lead Sponsor:
Universitair Ziekenhuis Brussel
Conditions:
Sars-CoV2
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus rapidly spread to t...
Eligibility Criteria
Inclusion
- Any adult employee of the UZ Brussel who provided a signed informed consent to participate in the study.
Exclusion
- UZ Brussel employees whose contract expires within 6 months of study initiation, with the exception of resident trainees (if training continues in another hospital, resident trainees will be asked to perform the last sampling when leaving the UZ Brussel).
- Staff not active during the inclusion period
Key Trial Info
Start Date :
May 12 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 25 2021
Estimated Enrollment :
3500 Patients enrolled
Trial Details
Trial ID
NCT04426292
Start Date
May 12 2020
End Date
December 25 2021
Last Update
November 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ Brussel
Jette, Brussels Capital, Belgium, 1090